Skip to content
Sign in
Artwork for Daybreak
Daybreak · August 19 · 11 min

Why Tata 1mg thinks speed is the wrong bet in pharma

Tata 1mg just reported revenue of nearly 3,000 crore rupees for the last financial year, roughly ten times what it earned when Tata took control, and it is turning a profit while much of the sector bleeds cash. In an e-pharmacy market obsessed with 10-minute delivery and deep discounts, 1mg won by doing the opposite. It capped its discounts and built its own labs and supply chain, and it treats fast delivery as a minor add-on. In this episode, we unpack why patience beats blitzscaling in Indian healthcare and what 1mg means when it calls healthcare longitudinal. Take The Great Rewiring survey here Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.

0:00-11:42
Play in

transcript

No transcript — this publisher did not publish one.

show notes

Tata 1mg just reported revenue of nearly 3,000 crore rupees for the last financial year, roughly ten times what it earned when Tata took control, and it is turning a profit while much of the sector bleeds cash.

In an e-pharmacy market obsessed with 10-minute delivery and deep discounts, 1mg won by doing the opposite. It capped its discounts and built its own labs and supply chain, and it treats fast delivery as a minor add-on.

In this episode, we unpack why patience beats blitzscaling in Indian healthcare and what 1mg means when it calls healthcare longitudinal.

Take The Great Rewiring survey here

Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.

links2

more episodes

All episodes